ArticleClinical and experimental immunology2000
The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA).
Article in Clinical and experimental immunology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Berberine in rheumatoid arthritis: a comprehensive review and meta-analysis of its anti-inflammatory and immunomodulatory mechanisms in animal models.Inflammopharmacology · 2025Pooled it
- Interleukin 12B gene polymorphisms and susceptibility to rheumatoid arthritis: a data synthesis.Clinical rheumatology · 2017Pooled it
- A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate.Annals of the rheumatic diseases · 2017Trial
- Rheumatoid factor production is genetically and molecularly distinct from rheumatoid arthritis.The Journal of clinical investigation · 2026Article
- Divergent roles of IL-35 and IL-39 in rheumatoid arthritis: restoring cytokine balance within the IL-12 family.Frontiers in immunology · 2026Review
- Decreased in-hospital mortality in shock patients with rheumatoid arthritis compared to those without: a retrospective analysis of a critical care database.Clinical rheumatology · 2025Observational
- Helper T cells: A potential target for sex hormones to ameliorate rheumatoid arthritis? (Review).Molecular medicine reports · 2024Review
- Dairy: Friend or Foe? Bovine Milk-Derived Extracellular Vesicles and Autoimmune Diseases.International journal of molecular sciences · 2024Review
- Genetic associations between autoimmune diseases and the risks of severe sepsis and 28-day mortality: a two-sample Mendelian randomization study.Frontiers in medicine · 2024Article
- The long non-coding RNA HOTAIR contributes to joint-specific gene expression in rheumatoid arthritis.Nature communications · 2023Article
- Exosomes derived from mesenchymal stem cells primed with disease-condition-serum improved therapeutic efficacy in a mouse rheumatoid arthritis model via enhanced TGF-β1 production.Stem cell research & therapy · 2023Article
- IL-15-producing splenic B cells play pathogenic roles in the development of autoimmune hepatitis.JHEP reports : innovation in hepatology · 2023Article
- Pregabalin inhibits proinflammatory cytokine release in patients with fibromyalgia syndrome.Archives of rheumatology · 2023Article
- The prognostic impact of rheumatoid arthritis in sepsis: a population-based analysis.Acute and critical care · 2022Article
- Associations between cytokine gene polymorphisms and rheumatoid arthritis in Turkish population.Northern clinics of Istanbul · 2020Article
- Bedside to bench: defining the immunopathogenesis of psoriatic arthritis.Nature reviews. Rheumatology · 2019Review
- Mesenchymal stem cell transplantation ameliorates Sjögren's syndrome via suppressing IL-12 production by dendritic cells.Stem cell research & therapy · 2018Article
- Bee Venom and Hesperidin Effectively Mitigate Complete Freund's Adjuvant-Induced Arthritis Via Immunomodulation and Enhancement of Antioxidant Defense System.Archives of rheumatology · 2018Article
- Attenuation of nociceptive pain and inflammatory disorders by total steroid and terpenoid fraction of Euphorbia tirucalli Linn root in experimental in vitro and in vivo model.Inflammopharmacology · 2018Article
- Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis.Annals of the rheumatic diseases · 2016Article
Corrections and comments
- Erratum issuedKim, WU [corrected to Kim, W]; Min SY [corrected to Min, S]; Cho, ML [corrected to Cho, M]; Min, DJ [corrected to Min, J]; Lee, SH [corrected to Lee, S]; Park, SH [corrected to Park, S]; Cho, CS [corrected to Cho, C]; Kim, HY [corrected to Kim, H]
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to investigate the role of IL-12 in patients with RA. IL-12 (p70) and its associated cytokines were measured in sera and synovial fluid (SF) using an enzyme-linked immunosorbent method. Seven American College of Rheumatology (ACR) core set measures as well as IL-12 levels were sequentially monitored at the commencement and 4 months after treatment with a low-dose steroid and disease-modifying anti-rheumatic drugs (DMARDs). In sera, 64 (42.2%) of 152 RA patients had detectable concentrations of IL-12 (p70), whereas one (1.4%) of 69 osteoarthritis (OA) patients and five (10%) of 50 healthy controls had detectable IL-12 (P < 0.001). The median level of circulating IL-12 was also higher in RA patients (P < 0.001). In SF, the number of patients with detectable IL-12 and the median IL-12 levels were significantly higher in RA patients (n = 53) than in OA patients (n = 22). In paired samples (n = 53) of sera and SF from RA patients, IL-12 levels were higher in the SF than in sera (P < 0.001). Patients with detectable IL-12 (n = 51) in sera had higher tender joint scores (P = 0.003), swollen joint scores (P < 0.001) and C-reactive protein (CRP; P = 0.036), than those without (n = 55). Four months after treatment with DMARDs, the improved group showed a larger IL-12 decrease than the non-improved group (P = 0.017). The levels of IL-12 correlated positively with those of IL-2, interferon-gamma, IL-6, and tumour necrosis factor-alpha, but were correlated inversely with those of IL-10. Our results demonstrate that IL-12 levels reflect RA disease activity and that IL-12 is involved in the production of proinflammatory cytokines. An IL-12 blockade could be useful for the treatment of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.